Mapping catheter for cardiac arrythmias cleared, launched
Biosense Webster announced the launch of an FDA-cleared catheter with novel technology for mapping cardiac arrythmias, including atrial fibrillation.
The Octaray Mapping Catheter with TRUEref Technology is powered by the Carto 3 Version 7 System, according to a press release from the company. The catheter has eight splines with improved electrode spacing options designed to provide shorter and more efficient mapping times than the Pentaray Nav Eco Mapping Catheter (Biosense Webster), which may shorten overall ablation procedure times, the company stated in the release.
The mapping catheter can map arrhythmias in any chamber, according to the release.
TRUEref Technology is a novel mapping reference electrode that is designed to reduce the impact of farfield signals, according to the release. The catheter has 48 small mapping electrodes on eight splines, reduced electrode size and tight electrode spacing.
“With shorter and more efficient mapping time, the catheter benefits both the patient and the physician, allowing for shorter procedure times while enabling greater accuracy and detail,” Michael Bodner, PhD, worldwide president of Biosense Webster, said in the release.
The mapping catheter is now available in the U.S., Europe, the Middle East and Africa.
Collapse
Read more about